ENTX Stock Overview
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Entera Bio Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.54 |
52 Week High | US$1.87 |
52 Week Low | US$0.52 |
Beta | 1.68 |
1 Month Change | 46.67% |
3 Month Change | 179.64% |
1 Year Change | 14.07% |
3 Year Change | -59.58% |
5 Year Change | -62.44% |
Change since IPO | -75.48% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Mar 23We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
May 31Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
Feb 15Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?
Oct 13Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M
Aug 11We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully
Jun 10Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth
Jan 21We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow
Oct 06Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Jun 19Entera Bio secures European patent for oral PTH formulations
Jun 17We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Mar 20Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely
Dec 05Entera Bio EPS misses by $0.22
Nov 19Entera Bio completes enrollment in Phase 2 trial of EB613 in Osteoporosis
Nov 09Shareholder Returns
ENTX | US Biotechs | US Market | |
---|---|---|---|
7D | 1.3% | 0.9% | 0.4% |
1Y | 14.1% | 10.3% | 28.8% |
Return vs Industry: ENTX exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: ENTX underperformed the US Market which returned 29.5% over the past year.
Price Volatility
ENTX volatility | |
---|---|
ENTX Average Weekly Movement | 20.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENTX's share price has been volatile over the past 3 months.
Volatility Over Time: ENTX's weekly volatility has increased from 14% to 20% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 18 | Miranda Toledano | https://www.enterabio.com |
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company’s lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency.
Entera Bio Ltd. Fundamentals Summary
ENTX fundamental statistics | |
---|---|
Market cap | US$54.64m |
Earnings (TTM) | -US$8.89m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.1x
P/E RatioIs ENTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$8.89m |
Earnings | -US$8.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.25 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ENTX perform over the long term?
See historical performance and comparison